Research and Development Expense of Vitro Biopharma, Inc. from 31 Jul 2010 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Vitro Biopharma, Inc. quarterly and annual Research and Development Expense in USD history and change rate from 31 Jul 2010 to 31 Oct 2025.
  • Vitro Biopharma, Inc. Research and Development Expense for the quarter ending 31 Oct 2025 was $117,504, a 40% decline year-over-year.
  • Vitro Biopharma, Inc. Research and Development Expense for the twelve months ending 31 Oct 2025 was $533,028, a 14% decline year-over-year.
  • Vitro Biopharma, Inc. annual Research and Development Expense for 2025 was $533,028, a 14% decline from 2024.
  • Vitro Biopharma, Inc. annual Research and Development Expense for 2024 was $618,270, a 200% increase from 2023.
  • Vitro Biopharma, Inc. annual Research and Development Expense for 2023 was $206,406, a 33% increase from 2022.
Source SEC data
View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)

Vitro Biopharma, Inc. Quarterly Research and Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $533,028 $117,504 -$79,214 -40% 01 Aug 2025 31 Oct 2025 10-K 13 Feb 2026 2025 FY
Q2 2025 $612,242 $119,210 -$6,418 -5.1% 01 May 2025 31 Jul 2025 10-Q 12 Sep 2025 2025 Q3
Q1 2025 $618,660 $222,431 +$82,742 +59% 01 Feb 2025 30 Apr 2025 10-Q 20 Jun 2025 2025 Q2
Q4 2024 $535,918 $73,883 -$82,352 -53% 01 Nov 2024 31 Jan 2025 10-Q 20 Mar 2025 2025 Q1
Q3 2024 $618,270 $196,718 +$96,738 +97% 01 Aug 2024 31 Oct 2024 10-K 13 Feb 2026 2025 FY
Q2 2024 $521,532 $125,628 +$92,482 +279% 01 May 2024 31 Jul 2024 10-Q 12 Sep 2025 2025 Q3
Q1 2024 $429,050 $139,689 +$73,242 +110% 01 Feb 2024 30 Apr 2024 10-Q 20 Jun 2025 2025 Q2
Q4 2023 $355,808 $156,235 +$149,402 +2186% 01 Nov 2023 31 Jan 2024 10-Q 20 Mar 2025 2025 Q1
Q3 2023 $206,406 $99,980 +$91,462 +1074% 01 Aug 2023 31 Oct 2023 10-K 28 Jan 2025 2024 FY
Q2 2023 $114,944 $33,146 -$45,925 -58% 01 May 2023 31 Jul 2023 10-Q 16 Sep 2024 2024 Q3
Q1 2023 $160,869 $66,447 +$976 +1.5% 01 Feb 2023 30 Apr 2023 10-Q 31 May 2024 2024 Q2
Q4 2022 $159,893 $6,833 +$4,263 +166% 01 Nov 2022 31 Jan 2023 10-Q 14 Mar 2024 2024 Q1
Q3 2022 $155,630 $8,518 01 Aug 2022 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q2 2022 $79,071 01 May 2022 31 Jul 2022 10-Q 28 Aug 2023 2023 Q3
Q1 2022 $65,471 01 Feb 2022 30 Apr 2022 10-Q 13 Jun 2023 2023 Q2
Q4 2021 $2,570 01 Nov 2021 31 Jan 2022 10-Q 14 Mar 2023 2023 Q1
Q1 2015 $182,860 $56,896 +$6,233 +12% 01 Feb 2015 30 Apr 2015 10-Q 22 Jan 2016 2015 Q2
Q4 2014 $176,627 $29,857 -$6,004 -17% 01 Nov 2014 31 Jan 2015 10-Q 24 Mar 2015 2015 Q1
Q3 2014 $182,631 $52,022 01 Aug 2014 31 Oct 2014 10-K 22 Sep 2016 2015 FY
Q2 2014 $44,085 +$16,542 +60% 01 May 2014 31 Jul 2014 10-Q 22 Sep 2014 2014 Q3
Q1 2014 $50,663 +$8,101 +19% 01 Feb 2014 30 Apr 2014 10-Q 22 Jan 2016 2015 Q2
Q4 2013 $35,861 01 Nov 2013 31 Jan 2014 10-Q 24 Mar 2015 2015 Q1
Q2 2013 $27,543 -$1,428 -4.9% 01 May 2013 31 Jul 2013 10-Q 22 Sep 2014 2014 Q3
Q1 2013 $42,562 -$133 -0.31% 01 Feb 2013 30 Apr 2013 10-Q 19 Jun 2014 2014 Q2
Q3 2012 $126,180 $24,930 -$7,478 -23% 01 Aug 2012 31 Oct 2012 10-K 12 Feb 2014 2013 FY
Q2 2012 $133,658 $28,971 -$6,914 -19% 01 May 2012 31 Jul 2012 10-Q/A 17 Oct 2012 2012 Q3
Q1 2012 $140,572 $42,695 +$15,132 +55% 01 Feb 2012 30 Apr 2012 10-Q/A 22 Jun 2012 2012 Q2
Q4 2011 $125,440 $29,584 -$12,598 -30% 01 Nov 2011 31 Jan 2012 10-Q 21 Mar 2012 2012 Q1
Q3 2011 $138,038 $32,408 01 Aug 2011 31 Oct 2011 10-K/A 16 Feb 2012 2011 FY
Q2 2011 $35,885 -$3,776 -9.5% 01 May 2011 31 Jul 2011 10-Q/A 17 Oct 2012 2012 Q3
Q1 2011 $27,563 01 Feb 2011 30 Apr 2011 10-Q/A 22 Jun 2012 2012 Q2
Q4 2010 $42,182 01 Nov 2010 31 Jan 2011 10-Q 21 Mar 2012 2012 Q1
Q2 2010 $39,661 01 May 2010 31 Jul 2010 10-Q/A 12 Oct 2011 2011 Q3

Vitro Biopharma, Inc. Annual Research and Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $533,028 -$85,242 -14% 01 Nov 2024 31 Oct 2025 10-K 13 Feb 2026 2025 FY
2024 $618,270 +$411,864 +200% 01 Nov 2023 31 Oct 2024 10-K 13 Feb 2026 2025 FY
2023 $206,406 +$50,776 +33% 01 Nov 2022 31 Oct 2023 10-K 28 Jan 2025 2024 FY
2022 $155,630 01 Nov 2021 31 Oct 2022 10-K 29 Jan 2024 2023 FY
2015 $152,019 -$30,612 -17% 01 Nov 2014 31 Oct 2015 10-K 22 Sep 2016 2015 FY
2014 $182,631 +$62,907 +53% 01 Nov 2013 31 Oct 2014 10-K 22 Sep 2016 2015 FY
2013 $119,724 -$6,456 -5.1% 01 Nov 2012 31 Oct 2013 10-K 13 Feb 2015 2014 FY
2012 $126,180 -$11,858 -8.6% 01 Nov 2011 31 Oct 2012 10-K 12 Feb 2014 2013 FY
2011 $138,038 -$39,470 -22% 01 Nov 2010 31 Oct 2011 10-K/A 16 Feb 2012 2011 FY
2010 $177,508 01 Nov 2009 31 Oct 2010 10-K/A 16 Feb 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.